How direct-to-patient clinical trial models can accelerate speed-to-market

Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market

Add bookmark

Pharma IQ
11/26/2020

We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

The uncertainty raised by the Covid-19 pandemic has forced the pharma industry to turn its resources toward strengthening clinical trial supply chains and improving patient access to care. In doing so, the industry has deepened its focus on patient-centricity and has expanded treatment options available for unknown diseases.

In this light, Pharma IQ has collaborated with PCI to explore the benefits, challenges and solutions of implementing direct-to-patient (DtP) supply chains in clinical trial settings, so that sponsors can streamline processes and increase speed to market, without compromising trial integrity or quality.

Download the report to receive exclusive expert-led insights and discover:

  • The importance of DtP services in the modern clinical trial delivery.
  • The benefits of developing a patient-centric clinical supply chain.
  • Best practices for connecting patients with an end-to-end solution.
  • How to drive the future of the DtP model to advance your clinical supply chain.

We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.

RECOMMENDED